Open Access Open Access  Restricted Access Subscription or Fee Access

Molecular Biology of Cancer Cell by Mutational Damage

Shubham Maurya

Abstract


It is now understood that the gradual accrual of mutations that result from genome damage is what causes normal cells to gradually change into cancer. Endogenous processes, such as mistakes in DNA replication, the inherent chemical instability of specific DNA bases, or an attack by free radicals produced during metabolism, can all lead to this damage. Exogenous agents like ionizing radiation, UV radiation, and chemical carcinogens can interact with DNA, causing DNA damage. Its capacity to fix this damage has developed inside cells, but variety of reasons, errors still happen and mutations, or permanent changes to the genome, are produced. Genes in charge of preserving integrity of the genome occasionally experience inactivating mutations that make it easier for new mutations to develop. Prior to identifying the fundamental causes of human cancer, this review looks for sources of mutational damage. Prevention might be achievable by comprehending the root reason. When a normal cell undergoes processes that cause mutational damage, genes required for normal homeostatic systems that regulate proliferation and death of cells become protected against cell death, known as oncogenes. Genes. The usually restrict proliferation, called as tumor suppressor genes, become inactive. After overcoming the typical restrictions on cell division and demise, a potential cancer cell now faces two new obstacles: it should overcome replicative senescence and become immortal, and it must get sufficient amounts of nutrients and oxygen to support this high
percentage of proliferation.


Full Text:

PDF

References


Bertram JS. The molecular biology of cancer. Mol Aspects Med. 2000 Dec 1;21(6):167–223. doi: 10.1016/s0098–2997(00)00007–8.

Bishop JM. The molecular genetics of cancer. Science. 1987 Jan 16;235(4786):305–11. doi: 10.1126/science.3541204.

Franks LM, Teich NM, editors. Introduction to the cellular and molecular biology of cancer. Oxford University Press; 1997.

Lang SH, Swift SL, White H, Misso K, Kleijnen J, Quek RGW. A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer. Int J Oncol. 2019 Sep 1;55(3):597–616. doi: 10.3892/ijo.2019.4842.

Wyrobek AJ, Eskenazi B, Young S, Arnheim N, Tiemann-Boege I, Jabs EW et al. Advancing age has differential effects on DNA damage, chromatin integrity, gene mutations, and aneuploidies in sperm. Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9601–6. doi: 10.1073/pnas.0506468103.

Weissleder R. Scaling down imaging: molecular mapping of cancer in mice. Nat Rev Cancer. 2002 Jan;2(1):11–8. doi: 10.1038/nrc701.

Oh SJ, Huh YM, Suh JS, Choi J, Haam S, Son JH. Cancer diagnosis by terahertz molecular imaging technique. J Infrared Milli Terahz Waves. 2012 Jan;33(1):74–81. doi: 10.1007/s10762–011–9847–9.

Lahtz C, Pfeifer GP. Epigenetic changes of DNA repair genes in cancer. J Mol Cell Biol. 2011 Feb 1;3(1):51–8. doi: 10.1093/jmcb/mjq053.

Esteller M. Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br J Cancer. 2006 Jan;94(2):179–83. doi: 10.1038/sj.bjc.6602918.

Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature. 1991 Jun;351(6326):453–6. doi: 10.1038/351453a0.

Dobzhansky T. Genetics of natural populations IX. Temporal Changes in the Composition of Populations of Drosophila Pseudoobscura. Genetics. 1943 Mar;28(2):162–86. doi: 10.1093/genetics/28.2.162.

Croce CM. Oncogenes and cancer. N Engl J Med. 2008 Jan 31;358(5):502–11. doi: 10.1056/NEJMra072367.


Refbacks

  • There are currently no refbacks.